This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
DaVita (DVA) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
DaVita's (DVA) dialysis services in the United States showcased solid results in Q1.
DaVita HealthCare (DVA) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 25.34% and 0.17%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for DaVita (DVA)This Earnings Season?
by Zacks Equity Research
DaVita (DVA) is expected to have gained from Kidney Care segment in Q1.
DaVita HealthCare (DVA) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
DaVita HealthCare (DVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: DaVita, EchoStar and PennyMac Financial Services
by Zacks Equity Research
Zacks.com featured highlights include: DaVita, EchoStar and PennyMac Financial Services
Should Value Investors Buy DaVita HealthCare (DVA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The Zacks Analyst Blog Highlights: InMode, Integer, Cardinal Health, DaVita and The Ensign Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: InMode, Integer, Cardinal Health, DaVita and The Ensign Group
3 Momentum Anomaly Stocks to Consider Amid Coronavirus Woes
by Zacks Equity Research
These fast movers are currently witnessing a short-term pullback in price as COVID-19 pandemonium batters market. So, this could essentially be a solid entry point for garnering profits.
5 Stocks to Buy for 5 Good Reasons
by Sejuti Banerjea
Here are 5 ways to make the most of a difficult market.
The Zacks Analyst Blog Highlights: DVA, CAH, TGNA, SLM and AMX
by Zacks Equity Research
The Zacks Analyst Blog Highlights: DVA, CAH, TGNA, SLM and AMX
Coronavirus-Led Volatility Rises: 5 High Earnings Yield Picks
by Zacks Equity Research
Dodge the COVID-19 pandemic by investing in these high earnings yield stocks.
5 Top Value Stocks to Buy in a Volatile April
by Nalak Das
Volatility is likely to persist in April as the panoptic impact of the coronavirus outbreak is yet to be realized in the United States and globally.
DVA or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Has DaVita (DVA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (DVA) Outperforming Other Medical Stocks This Year?
DaVita HealthCare (DVA) Stock Moves -0.46%: What You Should Know
by Zacks Equity Research
DaVita HealthCare (DVA) closed the most recent trading day at $76.06, moving -0.46% from the previous trading session.
Top Ranked Growth Stocks to Buy for March 31st
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, March 31st
Here's Why You Should Invest in DaVita (DVA) Stock Right Now
by Zacks Equity Research
DaVita (DVA) continues to gain traction from strong international foothold, strategic buyout of dialysis centers and DaVita Kidney Care.
Zacks.com featured highlights include: ITOCHU, Am??rica M??vil, Donegal, DaVita and The Cardinal Health
by Zacks Equity Research
Zacks.com featured highlights include: ITOCHU, Am??rica M??vil, Donegal, DaVita and The Cardinal Health
Use Relative Price Strength to Survive the Coronavirus Hysteria
by Nilanjan Choudhury
Want to try an out-of-the-box approach to earn handsome returns in the time of coronavirus? Tap these stocks with explosive relative price strength.
DaVita HealthCare (DVA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
DaVita HealthCare (DVA) closed at $75.27 in the latest trading session, marking a +0.19% move from the prior day.
DVA vs. CHE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (DVA) Outperforming Other Medical Stocks This Year?
DaVita HealthCare (DVA) Down 12.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Top Ranked Growth Stocks to Buy for March 10th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, March 10th
CVS Health's Latest Alliances to Fortify Kidney-Care Business
by Zacks Equity Research
With a growing incidence of chronic kidney diseases and end-stage renal failure in the United States, CVS Health's (CVS) new partnerships seem to be strategic.